scholarly journals Cystic fibrosis in the United Kingdom 1977-85: an improving picture. British Paediatric Association Working Party on Cystic Fibrosis.

BMJ ◽  
1988 ◽  
Vol 297 (6663) ◽  
pp. 1599-1602 ◽  
2020 ◽  
Vol 48 (2) ◽  
pp. 175-181
Author(s):  
A. Akan ◽  
E. Dibek-Mısırlıoğlu ◽  
E. Civelek ◽  
E. Vezir ◽  
C.N. Kocabaş

2020 ◽  
Vol 34 (8) ◽  
pp. 1764-1772
Author(s):  
J.P. Thyssen ◽  
Y. Andersen ◽  
A.‐S. Halling ◽  
H.C. Williams ◽  
A. Egeberg

BMJ ◽  
1993 ◽  
Vol 306 (6877) ◽  
pp. 549-552 ◽  
Author(s):  
S Walters ◽  
J Britton ◽  
M E Hodson

1998 ◽  
Vol 4 (4) ◽  
pp. 803-864 ◽  
Author(s):  
P.W. Wright ◽  
S.J. Burgess ◽  
R.G. Chadburn ◽  
A.J.M. Chamberlain ◽  
R. Frankland ◽  
...  

ABSTRACTThis paper considers the approaches currently used by life offices for statutory valuations, and proposes a number of changes to current practice. It builds on the earlier work of Philip Scott's Working Party and a working party which reported on all aspects of unitised with-profits business to the 1996 CILA conference.Recommendations are made for each of the major categories of long-term business, in particular for the introduction of a bonus reserve standard for accumulating with-profits business, whilst retaining the net premium standard for conventional with-profits business. It is proposed that the current net premium approach for non-profit business should be replaced by a gross premium method. The paper also develops a greater codification of the calculation of non-unit reserves on linked business.Considerable emphasis is placed on the requirement for statutory reserves to have regard to PRE. It is assumed throughout that the E.C. Third Life Directive remains in its current form.A number of examples are provided which illustrate the proposed method for accumulating with-profits business. Appendices to the paper include a draft of suggested consequential changes to the Insurance Companies Regulations 1994, and a revised supporting version of the whole of GN8.


2021 ◽  
Author(s):  
Owen W Tomlinson ◽  
Zoe L Saynor ◽  
Daniel Stevens ◽  
Don Urquhart ◽  
Craig A Williams

The COVID-19 pandemic has resulted in unprecedent change to clinical practice. As the impact upon delivery of exercise services for people with cystic fibrosis (CF) in the UK was unknown, this was characterised via a national survey. In total, 31 CF centres participated. Principal findings included a significant reduction in exercise testing, and widespread adaptation to deliver exercise training using telehealth methods. Promisingly, 71% stated that they would continue to use virtual methods of engaging patients in future practice. This does, however, highlight a need to develop sustainable and more standardised telehealth services further to manage patients moving forwards.


1995 ◽  
Vol 2 (4) ◽  
pp. 200-206 ◽  
Author(s):  
Carol Dezateux ◽  
Sara Godward

In 1969 universal clinical screening for neonatal hip instability was formally adopted in the United Kingdom with the aim of detecting and treating children considered to be at high risk of congenital dislocation of the hip (CDH). However, clinical screening is associated with both false positive and false negative diagnoses and has never been evaluated in a randomised trial. The emergence of hip ultrasound provides renewed impetus to reconsider and formally evaluate screening for CDH. Ultrasound imaging of the newborn hip may be used as a screening test and to assess and manage infants with clinically detected hip instability. Universal primary ultrasound screening has been adopted in some European countries, but enthusiasm for this new technology has been tempered by the subsequent large' increases in treatment and follow up. This paper reviews the existing evidence to support the different approaches to screening and describes the research agenda of the MRC working party on congenital dislocation of the hip. A randomised trial of screening is required to evaluate the policy options before ultrasound screening becomes widely adopted within the United Kingdom. The feasibility and acceptability of a trial need to be explored and key issues relating to trial design addressed.


Sign in / Sign up

Export Citation Format

Share Document